Origin Asset Management LLP Has $447,000 Stake in Medpace Holdings Inc (NASDAQ:MEDP)

Origin Asset Management LLP reduced its holdings in shares of Medpace Holdings Inc (NASDAQ:MEDP) by 86.2% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,584 shares of the company’s stock after selling 47,200 shares during the quarter. Origin Asset Management LLP’s holdings in Medpace were worth $447,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in MEDP. LS Investment Advisors LLC acquired a new stake in shares of Medpace in the 4th quarter valued at about $46,000. SHANDA ASSET MANAGEMENT HOLDINGS Ltd acquired a new stake in shares of Medpace in the 4th quarter valued at about $87,000. NumerixS Investment Technologies Inc acquired a new stake in shares of Medpace in the 4th quarter valued at about $119,000. South Dakota Investment Council acquired a new stake in shares of Medpace in the 1st quarter valued at about $189,000. Finally, Oppenheimer Asset Management Inc. acquired a new stake in shares of Medpace in the 4th quarter valued at about $198,000. 76.70% of the stock is owned by institutional investors and hedge funds.

MEDP traded up $0.79 on Wednesday, hitting $56.24. 8,765 shares of the company traded hands, compared to its average volume of 575,807. The company has a quick ratio of 0.69, a current ratio of 0.69 and a debt-to-equity ratio of 0.09. The company has a market cap of $1.98 billion, a PE ratio of 21.76, a P/E/G ratio of 1.67 and a beta of 1.42. Medpace Holdings Inc has a 12-month low of $41.50 and a 12-month high of $71.66.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, April 29th. The company reported $0.64 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.60 by $0.04. The firm had revenue of $200.70 million during the quarter, compared to the consensus estimate of $190.16 million. Medpace had a return on equity of 17.16% and a net margin of 10.49%. The firm’s revenue was up 23.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.60 EPS. As a group, sell-side analysts expect that Medpace Holdings Inc will post 2.64 EPS for the current fiscal year.

MEDP has been the subject of a number of research analyst reports. BidaskClub raised Medpace from a “hold” rating to a “buy” rating in a research report on Wednesday, March 20th. TheStreet cut Medpace from a “b” rating to a “c” rating in a research report on Friday, March 22nd. Robert W. Baird upped their target price on Medpace from $57.00 to $62.00 and gave the company a “neutral” rating in a research report on Tuesday, April 30th. Wolfe Research started coverage on Medpace in a research note on Tuesday, April 2nd. They set an “outperform” rating for the company. Finally, Zacks Investment Research raised Medpace from a “sell” rating to a “hold” rating and set a $63.00 price objective for the company in a research note on Wednesday, May 1st. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $59.25.

In other Medpace news, CFO Jesse J. Geiger sold 25,037 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $60.00, for a total transaction of $1,502,220.00. Following the completion of the sale, the chief financial officer now directly owns 25,037 shares of the company’s stock, valued at approximately $1,502,220. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Stephen P. Ewald sold 7,946 shares of the company’s stock in a transaction that occurred on Friday, March 29th. The shares were sold at an average price of $57.95, for a total value of $460,470.70. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 44,983 shares of company stock valued at $2,661,091. 24.20% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: “Origin Asset Management LLP Has $447,000 Stake in Medpace Holdings Inc (NASDAQ:MEDP)” was published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://transcriptdaily.com/2019/06/12/origin-asset-management-llp-has-447000-stake-in-medpace-holdings-inc-nasdaqmedp.html.

Medpace Company Profile

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Further Reading: Is it Safe to Invest in Commodities?

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings Inc (NASDAQ:MEDP).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.